Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.98 USD | -2.68% | -0.99% | +75.66% |
Jun. 05 | Y-mAbs Therapeutics, Inc. Appoints Norman LaFrance as Chief Development Officer | CI |
Jun. 01 | Y-mAbs Therapeutics, Inc. Announces Publication of Preclinical GD2-SADA Data | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+75.66% | 526M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+2.15% | 22.78B | |
-10.51% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- YMAB Stock
- News Y-mAbs Therapeutics, Inc.
- HC Wainwright Adjusts Price Target on Y-mAbs Therapeutics to $22 From $21, Keeps Buy Rating